Drug profile · INN
trisulfapyrimidines (sulfadiazine
TRIPLE SULFA
trisulfapyrimidines (sulfadiazine (TRIPLE SULFA) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — trisulfapyrimidines (sulfadiazine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
trisulfapyrimidines (sulfadiazine (TRIPLE SULFA) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial dihydropteroate synthase inhibitor
Primary target: Dihydropteroate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is trisulfapyrimidines (sulfadiazine?
trisulfapyrimidines (sulfadiazine (TRIPLE SULFA) is a bacterial dihydropteroate synthase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for trisulfapyrimidines (sulfadiazine?
TRIPLE SULFA is a marketed brand name for trisulfapyrimidines (sulfadiazine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trisulfapyrimidines (sulfadiazine?
trisulfapyrimidines (sulfadiazine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.